Al Czap, holder of three prior patents, has developed this new fourth patent pending delivery method. Al has been an industry leader and educator in preventive medicine since founding Thorne Research in 1984. He was the first to recognize the need for hypoallergenic ingredients and the first to devise methods of manufacture to deliver hypoallergenic products to an underserved patient population. Prior to his innovation and industry changing manufacturing techniques, patients with severely impaired immune and digestive system or patients compromised by environmental exposure had no place to turn. Al made products that were truly hypoallergenic and set the standard for treatment of all patients with nutritional medicine.
In 1996 Al began publishing the highly acclaimed, peer reviewed, indexed medical journal, Alternative Medicine Review. For 17 years, AMR was considered by preventive medical physicians to be the most authoritative reference and educational journal in its field. He continued publication of AMR for two years after his sale of Thorne to an investor group in 2010.
After experimenting unsuccessfully with semi-retirement, Al was drawn back to doing research through his new company, Czap R&D. Al has always been frustrated by the awareness that many important patient medical issues have not been effectively solved by the healthcare ecosystem. In particular, he has spent considerable time questioning assumptions taken for granted by the academic community that often undermine effective exploration of alternatives.
In 2015 Al’s exploration of drug delivery methodologies led him to the revelation that the perceived limitations of nutrient bioavailability could be shattered with an inventive and optimized approach to nano-level delivery. His resulting technological discoveries and patent filing form the backbone of what will quickly become the leading medical company in the industry, Tesseract Medical Research, LLC.